Home › Funds › Catalio Capital Management, LP › DFTX
Catalio Capital Management, LP position in DFTX
DEFINIUM THERAPEUTICS INC · Health Care
Catalio Capital Management, LP reported holding 562,672 shares of DFTX (DEFINIUM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$26.5M, representing 4.97% of its reported portfolio and ranking #6 among its reported holdings. Catalio Capital Management, LP has disclosed DFTX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's DFTX position evolved
Catalio Capital Management, LP first disclosed a stake in DFTX in Q1 2026 at 1,037,984 shares (US$19.6M). The position peaked in Q2 2026 at 562,672 shares, worth US$26.5M. Across 2 filings, Catalio Capital Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 562,672 shares valued at US$26.5M — a reduction of -475,312 shares quarter over quarter.. Notable position changes include a 46% trim in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.04M | $19.62M | New |
| Q2 2026 | 562.67K | $26.47M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DFTX and 13F data
DFTX (DEFINIUM THERAPEUTICS INC) is a Health Care company. 189 other funds we track also report a position in DFTX — the largest reported positions include Avoro Capital Advisors LLC (US$338.2M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$322.0M), Octagon Capital Advisors LP (US$138.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DFTX
- Avoro Capital Advisors LLC 7.19M sh · $338.17M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.85M sh · $322.00M · Q2 2026
- Octagon Capital Advisors LP 2.95M sh · $138.77M · Q2 2026
- Deep Track Capital, LP 2.75M sh · $129.36M · Q2 2026
- Commodore Capital LP 2.00M sh · $94.08M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.50M sh · $70.56M · Q2 2026
- Siren, L.L.C. 1.42M sh · $66.77M · Q2 2026
- Boxer Capital Management, LLC 998.50K sh · $46.97M · Q2 2026
- AWM Investment Company, Inc. 784.80K sh · $36.92M · Q2 2026
- ArrowMark Colorado Holdings LLC 564.07K sh · $26.53M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $25.87M · Q2 2026
- GREAT POINT PARTNERS LLC 425.00K sh · $19.99M · Q2 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held DFTX?
Catalio Capital Management, LP has disclosed DFTX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Catalio Capital Management, LP's current position in DFTX?
As of Q2 2026, Catalio Capital Management, LP holds 562.67K shares of DFTX (DEFINIUM THERAPEUTICS INC), valued at $26.47M, representing 4.97% of its reported portfolio and ranking #6.
Has Catalio Capital Management, LP been buying or selling DFTX?
In the latest 13F filing (Q2 2026), Catalio Capital Management, LP reduced its position in DFTX. The position peaked in Q2 2026 at 562.67K shares.
Which other funds hold DFTX?
Other major institutional holders of DFTX include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, Octagon Capital Advisors LP, among 189 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.